Objective: To identify an HIV epitope suitable for vaccine development.
Introduction
The HIV-1 pandemic has been caused by viral strains expressing structurally divergent versions of the coat protein gp120. The infection and previously tested vaccine candidates induce robust synthesis of antibodies to immunodominant gp120 regions, but these regions are mutable, and the antibodies display only strainspecific neutralization. Vaccine trials intended to induce antibody and cytotoxic T-cell responses did not reduce the risk of HIV infection in previous clinical trials [1, 2] , and the recent RV144 vaccine trial also illustrates the difficulties in inducing effective immune responses to the virus [3] . Consensus has developed that effective HIV vaccination will require identification of an epitope expressed in a sufficiently constant form by genetically diverse HIV strains found across the world and the induction of a robust immune response to such an epitope.
Antibodies from HIV-infected patients have been studied extensively for the ability to neutralize the virus [4] [5] [6] [7] [8] [9] [10] [11] . Rare monoclonal antibodies from infected patients neutralize HIV strains that are genetically divergent from the autologous virus [10, 12] . Only a minority of sera from HIV-infected patients express this capability, suggesting that production of broadly neutralizing antibodies to the conserved HIV epitope is immunologically disfavored [13] [14] [15] . Moreover, previously described monoclonal and polyclonal serum antibodies usually neutralize only a restricted set of group M primary HIV isolates when tested using the natural host cells, human T cells in primary culture. Very few structurally conserved epitopes that support broad neutralization by antibodies have been identified. These are the membrane proximal external region of gp41 [7] , a carbohydrate-dependent epitope of gp120 [6] , and a conformational epitope located in the CD4-binding site (CD4BS) of gp120 [16] . Binding to host CD4 receptors is obligatory for HIV infection of T cells and macrophages. The CD4BS is a large conformational determinant of discrete gp120 regions brought into spatial proximity by virtue of the threedimensional protein-folding pattern [17] [18] [19] [20] . Rare antibodies recognize the native CD4BS conformational state and neutralize the virus [13, 15] , but other anti-CD4BS antibodies display little or no neutralizing activity [4, 21, 22] .
Crystallography and mutagenesis studies indicate that the 421-433 peptide region provides essential amino acids forming the CD4BS [17] [18] [19] [20] . The sequence of residues 421-433 is mostly conserved in group M HIV-1 strains. This region is also distinguished by its B-cell superantigen character [23, 24] . A minority of preimmune antibodies produced without exposure to HIV bind the 421-433 epitope of gp120 [23] [24] [25] and proceed to catalyze the hydrolysis of gp120 [26, 27] . The preimmune antibodies may furnish a limited level of innate protection against infection, but there are no reports of broadly neutralizing antibodies to the 421-433 epitope induced by HIV infection. An impaired adaptive immune response to the epitope is consistent with its superantigenic character. Superantigens bind antibodies expressed as B-cell receptors by atypical interactions at conserved antibody framework regions [28] [29] [30] . Unlike conventional antigens, they do not stimulate efficient synthesis of classswitched antibodies [31] [32] [33] .
In the present study, we searched for neutralizing IgA to the 421-433 CD4BS region in three hemophilia A patients with prolonged HIV infection contracted by transfusion of contaminated blood products. We focused on IgA class antibodies, as IgA from noninfected humans previously showed low-level HIV neutralizing activity superior to IgG from the same subjects [27] . We report neutralization of diverse HIV strains with chemokine coreceptor CCR5 dependency by the IgA attributable to recognition of the 421-433 region. The exceptionally potent and broad antibody-neutralizing activity identifies this epitope as a major vulnerability of the virus suitable for targeting by an HIV vaccine. Our studies do not address the relationships between antibody production, immune system maturity, infection route, and disease progression. Future studies are necessary to investigate these points.
Methods

Patients
Peripheral blood was collected from three long-term survivors infected with HIV for 19-21 years who had not developed AIDS (LTS [19] [20] [21] IgA was purified from peripheral blood samples by affinity chromatography using immobilized antihuman a chain antibody ( [27, 34] ; see also Methods section of the Supplemental Digital Content, http://links.lww.com/ QAD/A43). IgA from donor 2866 (0.6 nmol) was subjected to two rounds of immunoadsorption with E-416-433b (3.7 nmol peptide equivalents) or control BSA (0.6 nmol, equivalent to the BSA content of E-416-433b; 18 h, 378C) in 10 mmol/l sodium phosphate pH 7.4, 137 mmol/l NaCl, 2.7 mmol/l KCl (PBS, 0.73 ml). Immune complexes were removed using anti-BSA antibody immobilized on agarose in the same buffer (0.2 ml settled gel; Sigma, St. Louis, Missouri, USA; 1 h rotary shaking). The unbound IgA in the supernatant (0.8 ml) was assayed for E-416-433b binding and HIV neutralization. The epitope-specific antibodies were prepared by binding of IgA pooled from the three LTS [19] [20] [21] donors (2 mg IgA; 12 nmol) to E-416-433 conjugated to agarose (35 nmol peptide equivalents/50 ml settled gel in 1 ml; 20 h with rotary shaking). Using a spin column, unbound IgA was removed with PBS (2 ml), noncovalently bound IgA was eluted with 0.1 mol/l glycine, pH 2.7 (0.4 ml; neutralized immediately with 0.025 ml, 1 mol/l Tris-HCl pH 9.0) and covalently bound IgA was eluted by treatment with 20 mmol/l pyridine 2-aldoxime methiodide (0.4 ml; Sigma; 17 h) followed by 0.1 mol/l glycine, pH 2.7. IgA was dialyzed against PBS prior to measuring E-416-433b binding and HIV neutralization activities.
ELISA was conducted to determine binding of antibodies, control proteins, or soluble CD4 (sCD4, four domains; Protein Sciences Corporation, Meriden, Connecticut, USA) to immobilized E-416-433b (70 ng peptide equivalents/well [35] ) or full-length recombinant gp120 (40 ng/well; subtype B, strain MN; Immunodiagnostic Inc. [36] , see also Methods section of the Supplemental Digital Content, http://links.lww.com/ QAD/A43). Binding of sCD4 was determined similarly using rabbit anti-CD4 serum for detection (1 : 1000; NIH AIDS Research and Reference Reagent Program). Covalent E-416-433a binding by IgA was determined by denaturing electrophoresis followed by staining with peroxidase-conjugated streptavidin [37] . IC50 values correspond to concentrations required to attain 50% inhibition of binding.
Clinical HIV isolates for neutralization assays were from the NIH AIDS Research and Reference Reagent Program. The strains were selected to represent multiple virus subtypes, availability of their gp120 sequence, and our ability to grow usable virus stocks at titer greater than 10 2.25 to 10 3 TCID50/ml in human peripheral blood mononuclear cells (PBMCs). Virus infection of phytohemagglutinin-activated PBMCs (pool of 8-12 healthy human donors) was measured in Carl Hanson's laboratory in PBS or varying IgA concentrations in PBS (four independent cultures/IgA concentration) using p24 enzyme immunoassay kits [38] . Additional assays were done in David Montefiori's laboratory by essentially the same method, except that the cultures were in duplicate and a mixture of PBMCs from two human donors served as the host cells [39] . Neutralization was determined by computing the reduction of p24 concentrations relative to infection in the presence of diluent instead of IgA. IgA concentrations yielding 50% neutralization (IC50) were obtained from fits of the data to the equation: neutralization (%) ¼ 100/ (1 þ 10 (logIC50 À log[IgA]) Â Hillslope) (GraphPad Prism, GraphPad Software Inc., La Jolla, California, USA; see Methods section of the Supplemental Digital Content for intra-assay and interassay variability analyses, http:// links.lww.com/QAD/A43).
Peptides
The electrophilic mimetics of gp120 residues contain the sequence of residues 416-433 (LPSRIKQIINMW-QEVGKA) and covalently reactive phosphonate diester groups placed at Lys side chains (E-416-433a and E-416-433b conjugated to bovine serum albumin). Alacontaining mutant 416-433 peptides, nonelectrophilic NE-416-433 peptide and sequence shuffled mutant 416-433 peptide (Sh416-433, GQKSWEIPAKNR-LIMVIQ) were from Sigma-Aldrich (St. Louis, Missouri, USA). Synthesis, purification, and analytical details are given in Methods section of the Supplemental Digital Content, http://links.lww.com/QAD/A43.
Results
IgA-binding activity Previously, we described weak HIV neutralization by IgA isolated from the blood of humans without HIV infection attributable to recognition of the 421-433 gp120 region (preimmune antibodies [27] ). Two subsets of preimmune antibodies to gp120 have been documented, one that binds the 421-433 region reversibly by traditional noncovalent means [23, 24] and another that degrades gp120 by a serine protease-like mechanism after completing the initial noncovalent binding step [27] .
Here, we used a single binding assay to detect both antibody subsets in IgA preparations from three patients 19-21 years of age after diagnosis of HIV infection (longterm survivors, LTS 19-21 patients). The assay employs mimetics of the 416-433 peptide region containing electrophilic phosphonate groups (E-416-433a and E-416-433b; Fig. 1a ). The peptide component of such mimetics binds antibodies noncovalently in coordination with covalent binding of the phosphonate to antibody nucleophilic sites responsible for proteolytic activity [26, 37] . Low-affinity peptide analogs of the 421-433 region have been reported to bind CD4 previously [40, 41] . E-416-433b was bound by all three LTS [19] [20] [21] IgA preparations at levels greater than IgA from humans without HIV infection determined by ELISA (Fig. 1b) . The binding was also detected by denaturing electrophoresis, indicating formation of covalent immune complexes by a subset of the antibodies (Fig. 1b , inset). Specificity of IgA pooled from the three LTS 19-21 donors for the 416-433 mimetic was evident from the representative competitive inhibition studies in Fig. 1c .
IgA from the three donors tested individually displayed similar reactivity with various reagents shown in this figure. IgA binding to immobilized E-416-433b was inhibited competitively by two soluble versions of the mimetic, E-416-433a and its nonelectrophilic 416-433 peptide counterpart (NE-416-433), but not the control shuffled sequence Sh416-433 peptide. The binding of IgA to E-416-433 was inhibited by gp120 but not by irrelevant proteins (e.g., ovalbumin), indicating conformational mimicry of the corresponding 416-433 region of the full-length protein (Fig. 1c ). NE-416-433 and gp120 are devoid of artificial electrophilic groups and do not bind covalently to antibodies. Therefore, their ability to inhibit the binding to E-416-433b indicates specific noncovalent recognition of the 416-433 epitope by the IgA. The importance of noncovalent IgA recognition of the epitope was also evident from maintenance of the E-416-433b binding activity in the presence of a small molecule electrophilic phosphonate hapten with [42] .
The IgA displayed binding to immobilized gp120 that was partially inhibited by E-416-433a and NE-416-433 but not the shuffled Sh416-433 peptide, suggesting that the epitope-specific antibodies constitute a significant subset of the overall gp120-binding IgAs (Fig. 1d ). In addition, soluble CD4 (sCD4), but not irrelevant proteins, inhibited IgA binding to E-416-433b and full-length gp120 ( Fig. 1c and e ), consistent with IgA recognition of the CD4BS. The ability of sCD4 to bind E-416-433b specifically and saturably was verified in direct-binding assays ( Fig. S2b and S2c of the Supplemental Digital Content, http://links.lww.com/QAD/A45).
The shorter E-421-433a and E-421-433b epitope mimetics inhibited E-416-433b binding by sCD4 ( Fig. S2d of the Supplemental Digital Content, http://links.lww.com/ QAD/A45), consistent with the essential role of the 421-433 peptide region in CD4 binding [17] [18] [19] [20] .
The importance of individual amino acids for noncovalent IgA recognition was evaluated from the competitive inhibition of E-416-433b binding by peptides containing Ala instead of the wild-type residues ( Table 1) . Peptides with Ala replacements at Ile420, Ile424, and Trp427 displayed 6.5-34.3-fold reduced inhibitory potency (IC 50 ) compared with the wild-type peptide. Ala replacements at seven additional positions resulted in reduced IC50 by at least two-fold (416, 419, 421, 423, 425, 430, and 432). Three of these residues are CD4-contacting residues from crystal studies (Asn425, Trp427, and Val430 [17, 18] ) and two additional residues are thought to contribute in CD4 binding from sitedirected mutagenesis studies (Lys421 and Lys432 [20] ). Taken together, the data indicate specific CD4BS recognition by IgA from the LTS 19-21 patients.
A few neutralizing antibodies to epitopes within or close to the CD4BS have been described. We studied the recognition of E-416-433b by three monoclonal antibodies with well defined specificity: monoclonal IgG b12 is described to bind an epitope overlapping the CD4BS [16] . Monoclonal IgG 17b and IgG 48d bind a conformational gp120 epitope exposed upon sCD4 binding [43] . These antibodies failed to bind E-416-433b ( Fig. S3 of the Supplemental Digital Content, http://links.lww.com/QAD/A46).
IgA-neutralizing activity
All three LTS [19] [20] [21] patients were infected with subtype B viral strains as determined by the sequences of the autologous virion gp120 gene (Table S1 of the Supplemental Digital Content, http://links.lww.com/ QAD/A48). HIV infection induces predominantly antibodies to the mutable gp120 epitopes with limited or no capacity to neutralize genetically heterologous HIV strains. We initially tested neutralization of a heterologous subtype C HIV strain to preferentially detect IgAs that neutralize the virus by recognizing the conserved HIV epitopes. The variable domain sequences of the autologous subtype B strains and heterologous subtype C test strain are substantially divergent (e.g., the V3 domain epitope shown in Fig. S4a of the Supplemental Digital Content, http://links.lww.com/QAD/A47). As predicted, the heterologous subtype C strain was not neutralized by mouse antibodies raised by immunization Binding of IgA (pooled from LTS 19-21 donors 2857, 2866, and 2886) to immobilized E-416-433b was measured in the absence and presence of increasing concentrations of the wild-type 416-433 peptide and mutant peptides containing Ala substitutions at individual positions (0.4-50 mg/ml) as in Fig. 1c . IC 50 values were determined from plots of residual IgA binding expressed as percentage of binding without competitor peptide versus competitor peptide concentration fitted to the equation: residual binding (%) ¼ 100/ (1 þ 10 (log[competitor peptide] À log[IC50]) ). Ratios of (IC50 mutant peptide / IC50 wild-type peptide ) higher than 2.0 indicate attenuated noncovalent binding of the mutants to IgA compared with the wild-type peptide. See Fig. 1c for example of competitive inhibition of IgA binding by the wild-type peptide. Yellow boxes, residues important for IgA binding that are also important for CD4 binding by gp120 as determined by crystallography (PDB 2B4C; [17] ) or site-directed mutagenesis [19, 20] . Green boxes, residues important for IgA binding but not known to play a role in gp120-CD4 binding.
with a subtype B gp120 ( Fig. S4b of the Supplemental Digital Content, http://links.lww.com/QAD/A47). In contrast, purified plasma IgA from all three LTS [19] [20] [21] patients neutralized the heterologous subtype C strain ( Fig. 2 and Table 2 ). We reported previously the weak HIV neutralizing activity of IgA from humans without HIV infection, evident only after extended IgA-virus incubations (24 h [27] ). At the shorter incubations times used here (1 h), the neutralizing activity of purified IgAs from noninfected individuals was negligible. There was no loss of host PBMC viability cultured with the LTS [19] [20] [21] IgA preparations without HIV, determined as in [38] . We also confirmed that the neutralizing activity of purified LTS [19] [20] [21] IgA cannot be attributed to endotoxin (Fig. S4c of the Supplemental Digital Content, http:// links.lww.com/QAD/A47), a contaminant that can induce release of chemokines with the potential of inhibiting HIV infectivity [44] . Like the purified IgAs, unfractionated plasma from LTS [19] [20] [21] patients also neutralized the virus (e.g., LTS [19] [20] [21] donor 2857 serum dilutions yielding 50% neutralization for subtype B strains QH0692 and PAVO, respectively, were 1 : 250 and 1 : 1735; for subtype C strains 97ZA009 and Du156, respectively, were 1 : 8132 and 1 : 192).
Eighteen genetically diverse, coreceptor CCR5-dependent clinical HIV isolates drawn from subtypes A, B, C, D, and AE were neutralized by each of the three LTS [19] [20] [21] IgA preparations ( Table 2 ). Neutralization of subtype C and B strains occurred with exceptional potency (submicrogram/ml range). For comparison, Table 2 shows the neutralizing activity of a reference monoclonal antibody tested in parallel, IgG b12.
To determine whether HIV neutralization is due to CD4BS recognition, the LTS [19] [20] [21] IgA was absorbed Fig. 3a ). In a separate experiment, we eluted the epitope-specific IgAs bound to immobilized E-416-433 agarose for neutralization tests. Two types of epitope-specific IgAs were tested, the noncovalently bound fraction recovered by acid elution and the covalently bound fraction eluted after pyridine 2aldoxime methiodide cleavage of the phosphonateantibody bonds. Our previous studies indicate that covalent binding of electrophilic peptides such as E-416-433 is predictive of the specific proteolytic activity of antibodies [37] . Enrichment of the epitope-specific IgA fractions eluted from the affinity column was evident from increased values of E-416-433b binding per unit IgA mass (Fig. S5a of the Supplemental Digital Content, http://links.lww.com/QAD/A50). The noncovalently and covalently bound IgA fractions eluted from the column also displayed increased HIV-neutralizing activity per unit IgA mass compared with the starting IgA preparation loaded on the column (respectively, by 38-fold and 1166-fold reduction of IC50; Fig. 3b ). Therefore, the neutralizing activity can be attributed to specific IgAs that recognize the 416-433 epitope.
The 416-433 epitope sequence of diverse HIV strains is largely but not fully conserved (Table S2 of the Supplemental Digital Content, http://links.lww.com/ QAD/A49). We evaluated the relationship between individual epitope mutations and IgA neutralizing potency using the consensus subtype C epitope sequence as reference ( Table 2 ; LPCRIKQIINMWQEVGKA). Only the R419 ! K, V430 ! A, and R432 ! K/Q mutations were individually associated with decreased neutralization regardless of the presence of other mutations ( Fig. 3c ; respectively, P < 0.0001, P < 0.0001, and P ¼ 0.025/ 0.006). Moreover, simultaneous mutations at positions 419, 430, and 432 were associated with decreased neutralization compared with the individual mutations ( Fig. S5b of the Supplemental Digital Content, http:// links.lww.com/QAD/A50). Table 1 indicates that Ala mutations at these positions also reduced IgA binding to the epitope peptide. Residues 430 and 432 are important for CD4 binding to gp120 [20] . The data confirm our conclusion that neutralization is attributable to IgAs that recognize the CD4BS. [19] [20] [21] IgA preparations in Table 2 for strains without and with mutations at individual amino acid positions were compared using the two-tailed Student's t-test. Mutations were identified by comparing the 17 HIV strains listed in Table S2 of the Supplemental Digital Content, http://links.lww.com/QAD/A49 with consensus subtype C epitope sequence, as subtype C strains were neutralized most potently by the IgAs. (*) IC50 for strains with the indicated consensus clade C residue. ( ) IC50 for strains with the indicated mutation.
As binding to host CD4 receptors is required for infection, diverse coreceptor CCR5-dependent HIV strains maintain the CD4BS in a mostly constant structure. We identified IgA class antibodies specific for the CD4BS 416-433 epitope produced by survivors of prolonged HIV infection that neutralized heterologous viral strains with exceptional potency. A conclusive determination of IgA specificity was possible through use of an electrophilic 416-433 peptide that mimics the CD4 binding function of the native CD4BS expressed by HIV. The corresponding region of full-length gp120 is expressed in a sterically accessible form on the protein surface [17, 18, 45] . IgA recognition of the CD4BS was confirmed by competitive inhibition of IgA binding to the electrophilic peptide and gp120 by CD4. Furthermore, mutation studies indicated the shared binding specificity of CD4 and the IgAs. Immunoadsorption and epitope-specific chromatography procedures indicated the 416-433 region as the major neutralizing epitope recognized by the IgA. This is corroborated by the observed association between certain epitope mutations and altered neutralizing potency. Consistent with recognition of the conserved CD4BS region, the IgAs neutralized genetically diverse HIV strains. The IgAs contain subsets of antibodies that bind gp120 noncovalently and antibodies that proceed to hydrolyze gp120 after completing the noncovalent binding step [27] . Our binding assays using the electrophilic 416-433 peptide mimetic detect both types of antibodies. We did not measure the contributions of these activities in virus neutralization. Noncovalent CD4BS binding alone is sufficient to neutralize the virus, and gp120 hydrolysis holds the potential of enhancing the neutralizing potency [26, 27] .
Adaptive synthesis of anti-CD4BS-neutralizing antibodies in the natural course of infection is widely acknowledged as an immunologically disfavored process [13, 15] . This is consistent with the superantigenic character of the 421-433 region of the CD4BS. The epitope is recognized weakly by the framework regions of antibodies produced without HIV infection that bind gp120 reversibly [29, 30] and catalyze its degradation [26, 27] . Superantigen binding to the B-cell receptor framework regions is thought to stimulate the cells nonproductively, and premature apoptosis occurs [31, 32] , consistent with infrequent production of neutralizing antibodies to the CD4BS. Serum antibodies to the 421-433 CD4BS epitope are also increased in the autoimmune disease systemic lupus erythematosus [46] , and recombinant antibodies to this epitope from lupus patients neutralize HIV [38] . HIV infection and lupus are rarely coexistent. We had assumed that the lupus antibodies are produced due to dysfunctional autoimmune reactivity. The studies reported here indicate that HIV infection itself stimulates production of powerful neutralizing antibodies to the CD4BS despite its superantigenic character. IgA concentrations in human blood are about 2 mg/ml [47] . Depending on the HIV-1 strain, the 50% effective concentrations of IgAs from the long-term survivors in Table 2 were 75-800 000-fold lower than the physiological IgA concentrations. HIV neutralization by unfractionated plasma from the three patients was also evident. We studied only three patients with very prolonged infection, and all three were positive for the neutralizing IgA. Also, our studies were limited to IgA from patients who contracted HIV by transfusion of contaminated blood products as children. Future research is needed to determine the time course of infectioninduced production of neutralizing IgAs, whether the neutralizing response is restricted to IgA class antibodies and whether the response can be induced by sexually transmitted infection occurring after the immune system has reached full maturity. Similarly, our findings do not necessarily imply that anti-CD4BS IgA production impedes HIV disease progression. Detailed longitudinal studies on a larger cohort of patients that take into account other host and viral factors known to influence disease progression are necessary to address these points.
HIV presents few epitopes suitable for vaccine targeting, reflecting an unusual capacity to evade traditional protective immunity mechanisms. The essential role of the 421-433 epitope in CD4BS binding and its sequence conservation qualify the epitope as a vaccine target. However, the superantigenic character of the epitope poses a challenge. The immune response to microbial infection is a stochastic process relying on certain highprobability B lymphocyte differentiation events. The process entails antigen binding to the antibody complementarity determining regions (CDRs), driving adaptive selection of somatically diversified B-cell receptors with the highest antigen-binding affinity. Understanding how B cells of the LTS 19-21 patients described here bypass restrictions on production of neutralizing anti-CD4BS antibodies may provide insight to designing a vaccine that induces similar antibodies. The potential bypass mechanisms are: (a) The B cells may slowly produce antibodies that bind the CD4BS via their CDRs with no utilization of the pre-existing CD4BS binding site located in the FRs; and (b) cellular downregulation due to CD4BS binding to the antibody FR site may be effectively counteracted by a favorable differentiation signal generated upon simultaneous engagement of another epitope on the same gp120 molecule by the CDRs. The latter bypass mechanism is supported by our recent report of antibodies with binary epitope reactivity directed to the 421-433 CD4BS epitope and another spatially distinct gp120 epitope induced by immunization of mice with an electrophilic mimetic of full-length gp120 [48] . Importantly, targeting of the 421-433 epitope is the first vaccine approach that induces the synthesis of antibodies with ability to neutralize genetically diverse HIV strains.
The inability to replicate the native structure of the CD4BS has held back development of a candidate vaccine that induces neutralizing antibodies to genetically diverse HIV strains. A conformational epitope recognized by monoclonal antibody b12 directed to the CD4BS was previously proposed as an HIV vaccine target [49] . Accurate mimicry of conformational epitopes, however, is difficult and efforts to develop a vaccine candidate mimicking the epitope recognized by antibody b12 have not been fruitful. The linear character of the 421-433 region should facilitate development of immunogens for induction of neutralizing antibody synthesis. Mimicry of the native 421-433 region of HIV by the E-416-433 probe is evident from its recognition by CD4 and neutralizing antibodies from infected individuals. Findings of potent and broad HIV neutralization by human antibodies to the 421-433 region described in the present study and the prospect of inducing accelerated synthesis of similar antibodies using experimental immunogens offer encouragement that an effective HIV vaccine directed to the CD4BS can be developed.
